Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C J Lord

Showing results (11-20 of 35) with videos related to

Pageof 4
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)|August 15, 1997
Congenic mapping of the insulin-dependent diabetes (Idd) gene, Idd10, localizes two genes mediating the Idd10 effect and eliminates the candidate Fcgr1P L Podolin, P Denny, C J Lord, et al.
Oncogene|May 10, 2011
Dysregulated TRK signalling is a therapeutic target in CYLD defective tumoursN Rajan, R Elliott, O Clewes, et al.
Genetics|May 3, 2001
Statistical modeling of interlocus interactions in a complex disease: rejection of the multiplicative model of epistasis in type 1 diabetesH J Cordell, J A Todd, N J Hill, et al.
Oncogene|March 12, 2013
Identification of novel determinants of resistance to lapatinib in ERBB2-amplified cancersD Wetterskog, K-K Shiu, I Chong, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 21, 2019
A decade of clinical development of PARP inhibitors in perspectiveJ Mateo, C J Lord, V Serra, et al.
Cold Spring Harbor Symposia on Quantitative Biology|July 28, 2006
Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancerA N J Tutt, C J Lord, N McCabe, et al.
Cytokine|June 17, 2000
Differential glycosylation of interleukin 2, the molecular basis for the NOD Idd3 type 1 diabetes gene?P L Podolin, M B Wilusz, R M Cubbon, et al.
Oncogene|August 13, 2013
A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancerS Postel-Vinay, I Bajrami, L Friboulet, et al.
Oncogene|May 20, 2020
Correction: A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1DS Rayter, R Elliott, J Travers, et al.
Genome Research|April 26, 2000
Congenic mapping of the type 1 diabetes locus, Idd3, to a 780-kb region of mouse chromosome 3: identification of a candidate segment of ancestral DNA by haplotype mappingP A Lyons, N Armitage, F Argentina, et al.
Pageof 4

Showing results (11-20 of 35) with videos related to

Sort By:
Pageof 4
Journal of Immunology (Baltimore, Md. : 1950)|August 15, 1997
Congenic mapping of the insulin-dependent diabetes (Idd) gene, Idd10, localizes two genes mediating the Idd10 effect and eliminates the candidate Fcgr1P L Podolin, P Denny, C J Lord, et al.
Oncogene|May 10, 2011
Dysregulated TRK signalling is a therapeutic target in CYLD defective tumoursN Rajan, R Elliott, O Clewes, et al.
Genetics|May 3, 2001
Statistical modeling of interlocus interactions in a complex disease: rejection of the multiplicative model of epistasis in type 1 diabetesH J Cordell, J A Todd, N J Hill, et al.
Oncogene|March 12, 2013
Identification of novel determinants of resistance to lapatinib in ERBB2-amplified cancersD Wetterskog, K-K Shiu, I Chong, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 21, 2019
A decade of clinical development of PARP inhibitors in perspectiveJ Mateo, C J Lord, V Serra, et al.
Cold Spring Harbor Symposia on Quantitative Biology|July 28, 2006
Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancerA N J Tutt, C J Lord, N McCabe, et al.
Cytokine|June 17, 2000
Differential glycosylation of interleukin 2, the molecular basis for the NOD Idd3 type 1 diabetes gene?P L Podolin, M B Wilusz, R M Cubbon, et al.
Oncogene|August 13, 2013
A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancerS Postel-Vinay, I Bajrami, L Friboulet, et al.
Oncogene|May 20, 2020
Correction: A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1DS Rayter, R Elliott, J Travers, et al.
Genome Research|April 26, 2000
Congenic mapping of the type 1 diabetes locus, Idd3, to a 780-kb region of mouse chromosome 3: identification of a candidate segment of ancestral DNA by haplotype mappingP A Lyons, N Armitage, F Argentina, et al.
Pageof 4